2018–19 Departmental Plan: Planned evaluation coverage over the next five fiscal years
| Program | Last evaluation | Evaluations planned in the next 5 years | Fiscal year of approval | 2018–19 Program spending covered by the planned evaluation (dollars) |
2018–19 Program spending covered by all planned evaluations (dollars) |
2018–19 Total program spending (dollars) | Rationale for not evaluating Program or spending |
|---|---|---|---|---|---|---|---|
Investigator-Initiated Research |
Evaluation of the Open Operating Grants Program 2012–13 |
Operating Support Program Evaluation |
2018–19 |
563,547,506 |
704,837,197 |
709,160,260 |
The components of the program not to be evaluated have low materiality, are not ongoing and/or were evaluated within the last five-year period. |
Canada Excellence Research Chairs Evaluation 2014–15 |
Canada Excellence Research Chairs Evaluation |
2019–20 |
4,200,000 |
||||
Not applicable |
Canada First Research Excellence Fund Evaluation |
2019–20 |
43,803,273 |
||||
Canada Research Chairs Program Evaluation 2016–17 |
Canada Research Chairs Program Evaluation |
2021–22 |
93,286,418 |
||||
Training and Career Support |
Evaluation of CIHR Salary/Career Award Programs 2012–13 |
Evaluation of the Training and Career Support Program |
2018–19 |
30,891,956 |
65,885,297 |
65,885,297 |
Not applicable |
Evaluation of the Vanier Graduate Scholarships Program 2014–15 |
Evaluation of the Vanier Graduate Scholarships Program |
2019–20 |
8,911,505 |
||||
Evaluation of the Banting Postdoctoral Fellowships Program 2014–15 |
Evaluation of the Banting Postdoctoral Fellowships Program |
2019–20 |
3,402,856 |
||||
Evaluation of the Canada Graduate Scholarships Program 2016–17 |
Evaluation of the Canada Graduate Scholarships Program |
2021–22 |
22,678,980 |
||||
Research in Priority Areas |
Not applicable |
Evaluation of the Dementia Research Strategy |
2018–19 |
4,938,075 |
233,144,226 |
299,964,368 |
The components of the program not to be evaluated have low materiality, are not ongoing and/or were evaluated within the last five-year period. |
Not applicable |
Evaluation of the Canadian Longitudinal Study on Aging |
2018–19 |
7,204,586 |
||||
Evaluation of the Collaborative Health Research Projects Program 2013–14 |
Evaluation of the Collaborative Health Research Projects Program |
2018–19 |
10,336,981 |
||||
Horizontal Evaluation of the Federal Initiative to Address HIV/AIDS in Canada 2014–15 |
Horizontal Evaluation of the Federal Initiative to Address HIV/AIDS in Canada |
2018–19 |
22,483,937 |
||||
CIHR 2011 International Review 2011–12 |
Review of the Institute of Infection and Immunity |
2018–19 |
3,213,831 |
||||
CIHR 2011 International Review 2011–12 |
Review of the Institute of Health Services and Policy Research |
2018–19 |
5,884,221 |
||||
CIHR 2011 International Review 2011–12 |
Review of the Institute of Gender and Health |
2018–19 |
6,715,497 |
||||
CIHR 2011 International Review 2011–12 |
Review of the Institute of Aging |
2018–19 |
5,832,119 |
||||
Evaluation of the College and Community Innovation Program 2012–13 |
Evaluation of the College and Community Innovation Program |
2018–19 |
210,188 |
||||
Evaluation of the Drug Safety and Effectiveness Network 2014–15 |
Evaluation of the Drug Safety and Effectiveness Network |
2019–20 |
7,678,446 |
||||
CIHR 2011 International Review 2011–12 |
Review of the Institute of Human Development, Child and Youth Health |
2019–20 |
5,862,038 |
||||
CIHR 2011 International Review 2011–12 |
Review of the Institute of Circulatory and Respiratory Health |
2019–20 |
7,228,026 |
||||
CIHR 2011 International Review 2011–12 |
Review of the Institute of Population and Public Health |
2019–20 |
5,200,216 |
||||
Not applicable |
Public Health Laboratories Evaluation |
2019–20 |
2,880,855 |
||||
Not applicable |
Evaluation of the Antimicrobial Resistance Initiatives |
2020–21 |
1,846,393 |
||||
CIHR 2011 International Review 2011–12 |
Review of the Institute of Aboriginal Peoples' Health |
2020–21 |
6,599,996 |
||||
Evaluation of the Institute of Neurosciences, Mental Health and Addiction 2016–17 |
Review of the Institute of Neurosciences, Mental Health and Addiction |
2020–21 |
4,941,889 |
||||
Evaluation of the Institute of Musculoskeletal Health and Arthritis 2016–17 |
Review of the Institute of Musculoskeletal Health and Arthritis |
2020–21 |
5,575,675 |
||||
Evaluation of the Business-Led Networks of Centres of Excellence Program 2015–16 |
Evaluation of the Business-Led Networks of Centres of Excellence Program |
2020–21 |
1,737,000 |
||||
Evaluation of the Networks of Centres of Excellence Program 2015–16 |
Evaluation of the Networks of Centres of Excellence Program |
2020–21 |
21,740,400 |
||||
Evaluation of the Institute of Cancer Research (2017–18) |
Review of the Institute of Cancer Research |
2021–22 |
6,701,462 |
||||
Evaluation of the Institute of Nutrition, Metabolism and Diabetes 2017–18 |
Review of the Institute of Nutrition, Metabolism and Diabetes |
2021–22 |
6,023,316 |
||||
Evaluation of the Strategy for Patient Orientated Research 2016–17 |
Evaluation of the Strategy for Patient Orientated Research |
2021–22 |
61,187,409 |
||||
Review of the Institute of Genetics 2017–18 |
Review of the Institute of Genetics |
2022–23 |
3,275,378 |
||||
Horizontal Evaluation of the National Anti-Drug Strategy 2017–18 |
Horizontal Evaluation of the Canadian Drugs and Substances Strategy (formerly known as National Anti-Drug Strategy) |
2022–23 |
4,190,286 |
||||
Evaluation of the Centres of Excellence for Commercialization and Research 2017–18 |
Evaluation of the Centres of Excellence for Commercialization and Research |
2022–23 |
13,194,408 |
||||
Evaluation of Gairdner 2017–18 |
Evaluation of Gairdner |
2022–23 |
461,598 |
||||
Internal Services |
Not applicable |
Not applicable |
Not applicable |
0 |
0 |
27,423,337 |
Historically at CIHR, internal services have not been evaluated as separate entities but risks associated with the ten services are considered in the conduct of the evaluations of programs, initiatives and institutes as they relate to the evaluation issues of design and delivery, and performance (effectiveness, efficiency and economy). |
Total |
Not applicable |
Not applicable |
Not applicable |
Not applicable |
1,003,866,720 |
1,102,433,262 |
- Date modified: